--- title: "Curis (CRIS) news: delisting, offering and Nasdaq notice" url: "https://aibio.space/companies/curis/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CRIS delisting, offering and Nasdaq notice news: Curis gets Nasdaq delisting determination over market value rule, plans to appeal. Curis, Inc." --- CRIS Curis, Inc. NASDAQ · United States # Curis (CRIS) news CRIS delisting, offering and Nasdaq notice news Financings · 2026-10-19 ## [Curis agrees to sell stock and warrants for about $8.5 million in gross proceeds](https://aibio.space/news/curis-agrees-sell-stock-warrants-about-8-5-million-gross-proceeds/) Curis sold shares and pre-funded warrants at an effective $0.51 a share, with common warrants at $0.60. A.G.P./Alliance Global Partners, the lead placement agent, earns a 6.5% cash fee on the gross proceeds. ## Latest Curis news 1. 2026-01-07 Financings [Curis raises $20.2 million up front in a PIPE that could bring in up to $80.8 million](https://aibio.space/news/curis-raises-20-2-million-up-front-pipe-could-bring-up-80-8-million/) The emavusertib developer sold preferred stock with three warrant series at $0.75, one of them timed to an enrollment goal in its leukemia trial. 2. 2025-08-22 Listings [Curis gets Nasdaq delisting determination over market value rule, plans to appeal](https://aibio.space/news/curis-gets-nasdaq-delisting-determination-market-value-rule-plans/) Nasdaq staff said Curis did not regain compliance with the $35,000,000 market value requirement by August 20, 2025. Curis must request a hearing by August 28, 2025; the request keeps its stock listed during the appeal. 3. 2025-08-22 Listings [Curis to appeal Nasdaq delisting after missing $35,000,000 market value rule](https://aibio.space/news/curis-appeal-nasdaq-delisting-after-missing-35-000-000-market-value/) Curis missed Nasdaq's $35 million market value rule and must ask for a hearing by August 28, 2025 to avoid delisting. It says it will ask, and its shares stay listed while a panel decides. 4. 2025-02-27 Listings [Curis gets Nasdaq deficiency notice on market value of listed securities](https://aibio.space/news/curis-gets-nasdaq-deficiency-notice-market-value-listed-securities/) Nasdaq told Curis that its listed securities were worth less than $35,000,000 for 30 consecutive business days. The company has until August 20, 2025 to regain compliance. ## Curis at a glance - **Ticker**: CRIS - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $5.1 million ### Related companies - [Apnimed](https://aibio.space/companies/apnimed/) NASDAQ: APMD - [VirExit Technologies](https://aibio.space/companies/virexit-technologies/) OTC: VXIT - [Candel Therapeutics](https://aibio.space/companies/candel-therapeutics/) NASDAQ: CADL - [AnaptysBio](https://aibio.space/companies/anaptysbio/) NASDAQ: ANAB - [Surrozen](https://aibio.space/companies/surrozen/) NASDAQ: SRZN - [Caris Life Sciences](https://aibio.space/companies/caris-life-sciences/) NASDAQ: CAI - [Novavax](https://aibio.space/companies/novavax/) NASDAQ: NVAX - [Vir Biotechnology](https://aibio.space/companies/vir-biotechnology/) NASDAQ: VIR ### Also on NASDAQ - [Acrivon Therapeutics](https://aibio.space/companies/acrivon-therapeutics/) ACRV - [Aclarion](https://aibio.space/companies/aclarion/) ACON - [Tempest Therapeutics](https://aibio.space/companies/tempest-therapeutics/) TPST - [Lumexa Imaging Holdings](https://aibio.space/companies/lumexa-imaging/) LMRI - [Trevi Therapeutics](https://aibio.space/companies/trevi-therapeutics/) TRVI - [Zentalis Pharmaceuticals](https://aibio.space/companies/zentalis-pharmaceuticals/) ZNTL ## Curis annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$7.6 million](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/) | [-$43.4 million](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/) | | Cash from operations | [-$27.2 million](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/) | [-$39.6 million](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/) | | Cash and equivalents | [$5.1 million](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000118/) | [$20.0 million](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000043/) | | Short-term investments | | [$0](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000031/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $5.1 million. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Curis Was Curis delisted? Our latest story on this, dated Aug 22, 2025: "Curis gets Nasdaq delisting determination over market value rule, plans to appeal". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curis-gets-nasdaq-delisting-determination-market-value-rule-plans/). Has Curis raised money recently? Our latest story on this, dated Jan 7, 2026: "Curis raises $20.2 million up front in a PIPE that could bring in up to $80.8 million". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curis-raises-20-2-million-up-front-pipe-could-bring-up-80-8-million/). Has Curis received a Nasdaq deficiency notice? Our latest story on this, dated Feb 27, 2025: "Curis gets Nasdaq deficiency notice on market value of listed securities". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/curis-gets-nasdaq-deficiency-notice-market-value-listed-securities/). What is the ticker symbol of Curis? Curis, Inc. trades under the ticker CRIS on NASDAQ. Where is Curis listed? Curis, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:CUS1; LS:A42DTL; LSX:A42DTL. What is the SEC CIK of Curis? The SEC Central Index Key (CIK) for Curis, Inc. is 1108205. Its filings are on SEC EDGAR. How many shares does Curis have outstanding? 2,090,077 shares as of 2026-08-11, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Curis listed under? Our directory records Curis, Inc. under United States. What does Curis do? Our directory classifies Curis, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline. What is the ISIN of Curis? The ISIN recorded for Curis, Inc. is US2312694084. Does aibio.space cover Curis? aibio.space lists Curis, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Curis incorporated? SEC records list its state or country of incorporation as DE. Is Curis profitable? Curis, Inc. reported a net loss of $7.6 million for the fiscal year ended Dec 31, 2025, and used $27.2 million of cash in operations, per its annual report to the SEC. How much cash does Curis have? $5.1 million in cash at Jun 30, 2026, per its 10-Q. What is the latest Curis (CRIS) stock news? Our latest story on Curis, dated Oct 19, 2026: "Curis agrees to sell stock and warrants for about $8.5 million in gross proceeds". Curis sold shares and pre-funded warrants at an effective $0.51 a share, with common warrants at $0.60. A.G.P./Alliance Global Partners, the lead placement agent, earns a 6.5% cash fee on the gross proceeds. [Source](https://aibio.space/news/curis-agrees-sell-stock-warrants-about-8-5-million-gross-proceeds/). ## Investor discussion: Curis Members talk about Curis (CRIS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Curis, newest first. Each line links the filing it comes from. 1. 2026-10-23 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1108205/000114036126040582/ef20084269_pre14a.htm) 2. 2026-10-19 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110465926116910/tm2627615d1_8k.htm) 3. 2026-08-10 Financings Filed a final prospectus for a securities offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000109/cris-sx1august2026.htm) 4. 2026-07-30 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000105/cris-20260724.htm) 5. 2026-07-01 Listings Reported a reverse stock split. SEC Form 8-K (Items 5.03). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000074/cris-20260625.htm) 6. 2026-06-25 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000071/cris-20260625.htm) 7. 2026-06-05 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000068/curis_2026specialmeetingrs.htm) 8. 2026-05-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000065/cris-20260519.htm) 9. 2026-05-22 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000066/curis_2026specialmeetingrs.htm) 10. 2026-05-01 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000056/cris-20260427.htm) 11. 2026-03-17 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000016/cris-20260317.htm) 12. 2026-02-13 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000009/criss-3resalepreferredstoc.htm) 13. 2026-02-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000006/cris-20260203.htm) 14. 2026-01-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000002/cris-20260107.htm) 15. 2025-11-06 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 1.02,2.01,2.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000105/cris-20251106.htm) 16. 2025-10-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000098/cris-20251020.htm) 17. 2025-08-22 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000093/cris-20250821.htm) 18. 2025-08-08 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000086/august2025atmprospectussup.htm) 19. 2025-07-02 Financings Reported a financing. SEC Form 8-K (Items 1.01,3.02,7.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000072/cris-20250701.htm) 20. 2025-05-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 3.03,5.02,5.03,5.07,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000053/cris-20250520.htm) 21. 2025-03-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.02,3.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000022/ex991unauditedfinancialinf.htm) 22. 2025-02-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/1108205/000110820525000020/cris-20250221.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CRIS on TradingView](https://www.tradingview.com/symbols/NASDAQ-CRIS/). ## SEC filings and registration - **SEC name**: Curis Inc - **CIK**: 1108205 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CRIS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 128 SPRING STREET, LEXINGTON, MA, 02421 - **Phone**: 617-503-6500 - **Shares outstanding**: 2,090,077 as of 2026-08-11 (10-Q filed 2026-08-14) ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1108205/000110465926116910/tm2627615d1_8k.htm) filed 2026-10-19 - [10-Q](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000118/cris-20260630.htm) filed 2026-08-14 - [S-1](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000109/cris-sx1august2026.htm) filed 2026-08-10 - [8-K](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000105/cris-20260724.htm) filed 2026-07-30 - [8-K](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000078/cris-20260702.htm) filed 2026-07-02 - [8-K](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000074/cris-20260625.htm) filed 2026-07-01 - [8-K](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000071/cris-20260625.htm) filed 2026-06-25 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1108205/000110820526000068/curis_2026specialmeetingrs.htm) filed 2026-06-05 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001108205), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Curis, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CRIS, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Curis, Inc. - **Ticker**: CRIS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biotechnology - **ISIN**: US2312694084 - **Other listed symbols**: GETTEX:CUS1; LS:A42DTL; LSX:A42DTL - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CRIS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/curis/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Curis (CRIS) news: delisting, offering and Nasdaq notice", 2026-10-31, https://aibio.space/companies/curis/